Vaxart, Inc. | TalkMarkets

Latest Posts

Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

Article By: Benzinga

Tuesday, May 4, 2021 7:59 AM EDT

Vaxart Inc has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.

In this article: VXRT Also: PFE, MRNA, BNTX

Read

Vaxart Slides After Reporting Delay Of Trial For Potential COVID-19 Oral Vaccine

Article By: The Fly

Monday, May 3, 2021 3:08 PM EDT

Shares of Vaxart are under pressure on Monday after the company reported worse-than-expected first quarter losses and said that its Phase II trial of VXA-CoV2-1 is now expected to start mid-year 2021 instead of in the second quarter.

In this article: VXRT

Read

2 Biopharma Stocks Looking To Make A Difference Against COVID-19: Technical Levels To Watch

Article By: Benzinga

Monday, May 3, 2021 1:17 PM EDT

Shares of Ocugen Inc. and Vaxart Inc. are moving Monday, May 3. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key variants of SARS-CoV-2.

In this article: VXRT, OCGN

Read

Market Briefing For Monday, Aug. 31

Article By: Gene Inger

Sunday, August 30, 2020 8:03 PM EDT

This continues our case for continued erratic behavior (rotating on news too); but not catastrophe, even if you get a shakeout of juggernauts along the way.

In this article: SPX, ABT, BMY, PFE, INO, SRNE, MRNA, HTBX, VXRT

Read